Neuronetrix’ COGNISION™ System
Alzheimer’s disease is a chronic neurodegenerative disease of the brain which afflicts roughly 5 million individuals in the United States. Approximately 10% of those over 65 and 50% of those over 85 will die as a result of Alzheimer’s disease.
Even with several therapies available to treat Alzheimer’s disease, there still is a significant gap between the onset of the disease and point at which treatment actually begins. This treatment gap is directly tied to the challenges in diagnosing the disease early, before the significant loss of memory, cognition, and activities of daily living. Patients, doctors, caregivers, and the pharmaceutical industry, are looking for and demanding a solution to this problem.
Neuronetrix’ COGNISION™ System will, for the first time, directly detect the abnormal cognitive effects of Alzheimer’s disease! This will facilitate an earlier and more accurate diagnosis than is currently available. Physicians will use the COGNISION™ test to determine which patients would benefit from the available drug treatments. The system can also be used to monitor the efficacy of the prescribed therapy.
With the aging of America and the proliferation of new Alzheimer’s therapies, the market for Alzheimer’s screening could approach several billion dollars per year in the United States alone.
Following the validation of the COGNISION™ System for Alzheimer’s disease, Neuronetrix will expand into other neurodiagnostic markets such as ADHD, dyslexia, and depression.
http://www.neuronetrix.com/